The turnover decline reflected lower volumes in the domestic market and a prudent commercial strategy focused on high value projects.
“In a year with significant challenges for the entire agribusiness sector, Norofert acted with prudence and focused on its core activity – production and commercialization of bacteria-based solutions developed in the Filipeștii de Pădure laboratory. Also, this year, we advanced with the investments in irrigation and in the factory in Brazil, and in October we reached a new stage in international expansion with the official launch of the facility. In the United States, the revenues already account for approximatively 10% of the revenue recorded in the first nine months of 2025,” stated Vlad Popescu, President of the Board, Norofert.
He added the main medium-term objective remains the consolidation of the company’s presence on the US and Brazil markets, which are likely to generate as much as 40% of the group’s turnover in the next three years.
The new production facility in Chapeco, Brazil, developed in partnership with the Engenutri Group, became operational in October. The facility has a capacity of 15,000 liters per day and uses bacteria produced in the Filipeștii de Pădure research laboratory, a center of excellence for agricultural biotechnology and the core of the company research activities.
Operating revenues reached RON 35 million, down 8%, influenced by lower volumes in the domestic market and by a prudent commercial approach.
Operating result went up by 84%, reaching RON 7.7 million, supported by improved efficiency and cost optimization.
(English version by Catalina Apostoiu)